Roniciclib

CAS No. 1223498-69-8

Roniciclib ( BAY 10-00394;BAY1000394 )

Catalog No. M10856 CAS No. 1223498-69-8

A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Roniciclib
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
  • Description
    A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM; inhibits 16 additional kinase in a panel of 214 non-CDK Ser/Thr and Tyr kinases; simultaneously inhibits cell-cycle progression and RNA polymerase II-mediated gene transcription, shows broad and uniform inhibitory activity on cell proliferation with IC50 of 8-33 nM, potently inhibits growth of various human tumor xenografts.Lung Cancer Phase 2 Discontinued
  • Synonyms
    BAY 10-00394;BAY1000394
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    1223498-69-8
  • Formula Weight
    430.44
  • Molecular Formula
    C18H21F3N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@H](O)[C@H](OC1=NC(NC2=CC=C(S(=N)(C3CC3)=O)C=C2)=NC=C1C(F)(F)F)C
  • Chemical Name
    (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Siemeister G, et al. Mol Cancer Ther. 2012 Oct;11(10):2265-73.
2. Lücking U, et al. ChemMedChem. 2013 Jul;8(7):1067-85.
3. Ayaz P, et al. ACS Chem Biol. 2016 Jun 17;11(6):1710-9.
4. Bahleda R, et al. Br J Cancer. 2017 Jun 6;116(12):1505-1512.
molnova catalog
related products
  • CCT-251921

    A potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively.

  • GW-8510

    GW-8510 (GW8510) is apotent, selective inhibitor of CDK2 with IC50 of 10 nM; displays weak inhibition for CDK1 and CDK4 (IC50=110 and 130 nM, respectively) in vitro biochemical assays.

  • AZD-5438

    A potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively; also inhibits the kinase activity of p25-Cdk5 (IC50=14 nM) and GSK-3β (IC50=17 nM) in vitro.